RLAY Q4 2021 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$567,000-99.3% YoY

Gross Profit

-$51M-8908.8% margin

Operating Income

-$68M-11944.1% margin

Net Income

-$67M-11897.0% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

-14.9%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$41M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$111M

Stockholders' Equity

$898M

Cash & Equivalents

$280M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$567,000	$83M	-99.3%
Gross Profit	-$51M	$82M	-161.8%
Operating Income	-$68M	$35M	-293.6%
Net Income	-$67M	$35M	-291.2%